干扰素诱导HBV基因突变后再次抗病毒疗效  

The second antiviral efficacy after interferon-induced HBV gene mutation

作　　者：刘盼[1] 余祖江[1] 

机构地区：[1]郑州大学第一附属医院感染科,河南郑州450052

出　　处：《河南医学研究》2014年第2期25-27,共3页Henan Medical Research

摘　　要：目的:探讨慢性乙型肝炎(CHB)患者应用普通干扰素(IFN)诱导HBV基因突变后的再次抗病毒疗效。方法:选择44例持续接受IFN治疗无效者检测出HBV-C区[C基因启动子(CP)/前C/C基因]突变的CHB患者,根据其再次抗病毒治疗药物的选择,分为聚乙二醇干扰素(PEG-IFN)组(A组)和拉米夫定组(B组),分析治疗6个月后HBV-DNA及ALT的变化。结果:抗病毒治疗6个月后,A组的ALT复常率及HBV-DNA阴转率分别为31.25%和37.50%,B组分别为75.00%和82.14%,两组差异有统计学意义(P<0.05)。结论:IFN诱导HBV-C区基因突变后,拉米夫定较PEG-IFN抗病毒疗效好。Objective ： To explore the efficacy of the second antiviral treatment after common inter- feron-induced HBV gene mutation. Methods： 44 patients with HBV-C region [ core promoter （CP） and the precore/core gene] mutations after common interferon treatment were collected. Then they were divided into group A （treated by pegylated interferon） and group B （treated by lamivudine） according to different anti-virus drugs. The changes of the levels of HBV-DNA and ALT in two groups were analyzed after 6 months＇ treatment. Results： The rates of ALT normaliza- tion and HBV-DNA negative-converting were 75. 00% , 82. 14% in group A and 31. 25% , 37.50% in group B, the differences were of statistical significance antiviral efficacy of Lamivudine is better than pegylated interferon duced HBV-C area gene mutation. P 〈 0.05 ）. Conclusion ： The n patients with interferon-in-

关 键 词：慢性乙型肝炎 干扰素诱导突变 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]